menu
    • menu
    [{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Not Applicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Not Applicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved","graph3":"Recordati","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recordati \/ Tolmar International","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Tolmar International"},{"orgOrder":0,"company":"Recordati","sponsor":"Eusa Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved","graph3":"Recordati","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Not Applicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Not Applicable"},{"orgOrder":0,"company":"Recordati","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ITALY","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recordati \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"Recordati","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Sutimlimab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Recordati","amount2":1.0800000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Recordati"}]

    Find Clinical Drug Pipeline Developments & Deals by Recordati

    Menu

    Recordati

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Sanofi

                            Deal Size : $1,075.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Recordati Buys Rights to Rare Immune Disorder Drug from Sanofi for $825M

                            Details : Recordati will acquire the global rights to Enjaymo (sutimlimab), a biologic and the only approved targeted product for cold agglutinin disease, a rare B-cell lymphoproliferative disorder.

                            Brand Name : Enjaymo

                            Molecule Type : Large molecule

                            Upfront Cash : $825.0 million

                            October 04, 2024

                            Lead Product(s) : Sutimlimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Sanofi

                            Deal Size : $1,075.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : ARS Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            ARS Pharmaceuticals Reacquires European Marketing Rights to Neffy® (ARS-1) for the Treatment of Type I Allerg...

                            Details : Under the agreement, ARS Pharmaceuticals Reacquires commercial rights to neffy (ARS-1) in the European region. Neffy is an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions leading to ...

                            Brand Name : Neffy

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : ARS Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Osilodrostat Phosphate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 ...

                            Details : Isturisa (osilodrostat phosphate) is an oral inhibitor of 11β-hydroxylase (CYP11B1), which catalyses the final step of cortisol synthesis in the adrenal glands. Isturisa® is available as 1 mg, 5 mg and 10 mg film-coated tablets.

                            Brand Name : Isturisa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 31, 2022

                            Lead Product(s) : Osilodrostat Phosphate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Osilodrostat Phosphate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Recordati Rare Diseases Announces Several Scientific Abstracts to Be Presented at the Upcoming Endo Society An...

                            Details : ISTURISA (osilodrostat), is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.

                            Brand Name : Isturisa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 08, 2022

                            Lead Product(s) : Osilodrostat Phosphate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Eusa Pharma

                            Deal Size : $847.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Recordati to Acquire Eusa Pharma (UK) Ltd, A Global Specialty Pharmaceutical Company Focused on Rare and Niche...

                            Details : Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small ...

                            Brand Name : Qarziba

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 03, 2021

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Eusa Pharma

                            Deal Size : $847.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Tolmar

                            Deal Size : $168.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Recordati: License Obtained for the Commercialization of Eligard in Europe and Other Countries

                            Details : Eligard® is a marketed medicinal product for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

                            Brand Name : Eligard

                            Molecule Type : Peptide

                            Upfront Cash : $42.1 million

                            January 29, 2021

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Tolmar

                            Deal Size : $168.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Osilodrostat Phosphate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Recordati Reports Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatm...

                            Details : Data from the Phase III LINC-3 study, published in Lancet Diabetes & Endocrinology, demonstrate that Isturisa® (osilodrostat) rapidly decreases mean urinary free cortisol (mUFC) in patients with Cushing’s disease.

                            Brand Name : Isturisa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 28, 2020

                            Lead Product(s) : Osilodrostat Phosphate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed

                            Recordati

                            Italy arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Osilodrostat Phosphate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Recordati Submits New Drug Application for ISTURISA® in Japan

                            Details : In the Phase 3 LINC?3 study, a significantly higher proportion of patients treated with Isturisa® (osilodrostat) maintained normal mean urinary free cortisol (mUFC) at the end of the 8?week.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 26, 2020

                            Lead Product(s) : Osilodrostat Phosphate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth